drugset / Trial / NCT05546879
Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC
NaSingle-groupOpen-labelTreatment
Summary
The study will assess the safety of the association of NP137 with the standard of care Atezolizumab-Bevacizumab in first line setting in patients with unresectable hepatocellular carcinoma. The study drug which is tested is the NP137 in association with Atezolizumab-Bevacizumab to allow a better tumor response as well as better survival outcomes with an acceptable safety.
Timeline
- Start
- 2023-03-15
- Primary completion
- 2026-03-19
- Completion
- 2029-03-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NP137 | Monoclonal antibody | 9 mg/kg | Intravenous |
| Subject | NP137 | Monoclonal antibody | 14 mg/kg | Intravenous |
| Background | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Background | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |